Home > About Us > CNIO Publications

CNIO Publications

RPAP1 regulates the activity of RNA polymerase II by means of its interaction with gene transactivat

Cell Reports

The RPAP1 protein, essential for cell identity and viability

Madrid, 18 January, 2018

The regulation of the activity of RNA polymerase II, which catalyses the transcription of DNA in order to generate messenger RNA, is central to cell differentiation and the maintenance of cell identity. RPAP1 is a protein associated with this enzyme whose function in mammals was unknown up until now. A study carried out at the Spanish National Cancer Research Centre (CNIO) and the Institute for Research in Biomedicine (IRB) in Barcelona, demonstrates its key role in establishing and preserving...

Read more...
Nabil Djouder, head of the Growth Factors, Nutrients and Cancer Group at the CNIO

Cell Metabolism

Researchers suggest specific diets for preventing colorectal cancer in high-risk groups

Madrid, 21 December, 2017

Colorectal cancer is the most prevalent malignant tumour in Spain. It is known that factors such as diet and intestinal inflammation play an important role in its occurrence, but direct links between nutrients, inflammation and colorectal cancer are poorly described. Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered that the amount of protein in our diet may be an important factor in the prevention of colorectal cancer in different risk groups. People already...

Read more...
Histology of a glioblastoma induced by the silencing of RanBP6./ CNIO

Nature Communications

Novel mechanism that protects from glioblastoma identified

Madrid, 18 December, 2017

A group of researchers at the Spanish National Cancer Research Centre (CNIO) have identified a protein called RanBP6 as a new regulator of EGFR. In a paper published in Nature Communications they show how silencing of RanBP6 promoted glioma growth, by upregulating EGFR expression. Moreover, reconstitution of RanBP6 in a mouse xenograft model leads to reduction in tumor growth. Authors state that these findings might have “important clinical implications”.Malignant brain tumors represent about...

Read more...
The first effective therapy against glioblastoma by attacking telomeres

Cancer Cell

The first effective therapy against glioblastoma by attacking telomeres

Madrid, 13 November, 2017

The Telomere and Telomerase Group at the Spanish National Cancer Research Centre (CNIO) has shown that it is possible to block the growth of human and murine glioblastoma in mouse models by blocking the TRF1 protein; an essential component of the telomere-protective complex known as shelterin. The study, published in Cancer Cell, describes a new and promising way to combat this type of brain tumour, considered one of the most lethal and difficult to treat, by attacking its ability to...

Read more...
The PI3K pathway and TRF1, essentialfor the integrity of telomeres, are functionally connected.

Nature Communications

Two important signalling pathways in cancer and ageing are connected for the first time

Madrid, 2 November, 2017

The structure of proteins that protect telomeres (shelterin proteins, from “protective shield”) are promising targets to combat cancer but to date there has been no drug or effective form for attacking them. In the absence of drugs that destroy telomeres, cancer retains one of its most terrible properties, which is the ability of its cells to perpetually divide. Two years ago, the group led by Maria A. Blasco at the Spanish National Cancer Research Centre (CNIO) hit upon several compounds that...

Read more...

Genes and Development

'Capicua’ gene plays a key role in T-cell acute lymphoblastic leukaemia

Madrid, 21 September, 2017

Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukaemia. In a paper published this week in the printed edition of Genes and Development, the scientists explain how the mice in which a specific gene, known as Capicua, has been inactivated, inevitably develop this type of leukaemia. They have also discovered...

Read more...

PNAS

A way to stabilize haploidy in animal cells

Madrid, 14 August, 2017

The emergence, in recent years, of the first mammalian haploid cell lines has raised great expectations in the scientific community. Despite their potential, these cultures present some issues that make their use complicated because Haploidy is unstable and can be lost quickly. The Genomic Instability Group at the Spanish National Cancer Research Centre (CNIO) has offered an explanation of this phenomenon and proposes a way to overcome it. Their work has been published this week in the...

Read more...

Nucleic Acids Research

New computational method enhances our understanding of the human epigenome

Madrid, 3 August, 2017

A team of scientists from different institutions such as the BSC, the Newcastle University and the Spanish National Cancer Research Centre (CNIO) has developed a method to detect the epigenome areas where the changes that give rise to cellular diversity originate. These changes are also related to the cancer origin and development. In the study, which has been published in Nucleic Acids Research, they have developed a computational method that has been applied in hematopoiesis, the process of...

Read more...

Nature

A Braf kinase-inactive mutant induces lung adenocarcinoma

Madrid, 2 August, 2017

The initiating oncogenic event in almost half of human lung adenocarcinomas is still unknown, a fact that complicates the development of selective targeted therapies. Yet these tumours harbour a number of alterations without obvious oncogenic function including BRAF-inactivating mutations. Researchers at the Spanish National Cancer Research Centre (CNIO) have demonstrated that the expression of an endogenous Braf (D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A)...

Read more...

Clinical Cancer Research

New mutations related to hereditary neuroendocrine tumours

Madrid, 20 July, 2017

Pheochromocytomas and paragangliomas are rare neuroendocrine tumours with a strong hereditary component. Half the genes whose alterations confer hereditary susceptibility to develop this condition code for enzymes involved in the Krebs cycle, a metabolic route involved in cellular respiration. A study by the Hereditary Endocrine Cancer Group of the Spanish National Cancer Research Centre (CNIO) published in the journal Clinical Cancer Research identifies new genes associated with this cycle...

Read more...